Independent testing laboratory and formulation firm Digipath, Inc. has announced that its GroSciences division has completed preliminary validation testing on its natural plant-derived pesticide TERPO+ Broadspectrum that awaits patenting.
This product has the potential to serve a massive market and protect marijuana plants from microorganisms.
Testing has proven that TERPO+ Broadspectrum serves as a treatment for eliminating microbial bioburden on hemp and cannabis plants. Microbial bioburden and microorganism are the biggest contributors in cannabis plant loss.
Recent experiments on cannabis flower have shown that GroSciences’ TERPO+ Broadspectrum is effective in decontaminating cannabis and hemp plants, and ensures that cannabis samples are within most states’ testing limits.
Test results show that TERPO+ Broadspectrum reduced CFU/g with up to 91% compared to untreated samples.
According to the Chief Science Officer of Digipath Inc. Dr. Cindy Orser, the preliminary validation test successfully treated a sample that had failed a state microbial test previously.
After treatment with TERPO+ Broadspectrum, the sample passed the test.
Denkin said that a product like TERPO+ Broadspectrum could treat plants material effectively and help make it a sellable product with huge potential. He added that they would continue moving forward with product development and testing so that they can introduce it to the market soonest possible.